Clementia is a clinical stage biopharmaceutical company committed to delivering treatments to people who have none. The company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat fibrodysplasia ossificans progressiva (FOP), multiple osteochondroma (MO), and other diseases.
Copyright Nasdaq. Minimum 15 minutes delayed.
There are no items to display.